Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025

Plain-English Summary: Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025

The Uterine Fibroid Intervention and Gynecological Health Treatment Act of 2025 (sometimes referred to by the acronym "UF-IGHT Act") is a Senate bill focused on improving how uterine fibroids and related gynecological conditions are researched, treated, and managed within the U.S. healthcare system. Uterine fibroids are noncancerous growths that develop in or around the uterus and affect millions of women, often causing significant pain, heavy bleeding, and other health complications. Because no official description has been provided, the specific details of the bill are not fully available, but based on its title, it appears aimed at expanding access to treatment options and potentially increasing research funding for these conditions.

If the bill follows the pattern of similar legislation, it would likely affect women — particularly those of reproductive age — who are living with uterine fibroids or other gynecological health issues. It may also affect healthcare providers, insurance companies, and federal health agencies like the National Institutes of Health (NIH), potentially by directing more resources toward diagnosis, treatment, and awareness.

The bill was introduced in the Senate and has been referred to the Committee on Health, Education, Labor, and Pensions (HELP), where hearings have already been held. This means it is still in an early stage of the legislative process and has not yet been voted on. Americans interested in this bill — especially those personally affected by uterine fibroids — may want to follow its progress as more details become available.